Afya and Yduqs signed a merger agreement on September 23, 2026, creating a combined group with R$9.4 billion in revenue and roughly 5,900 annual medical-school seats, subject to antitrust review …
Afya and Yduqs signed a merger agreement on September 23, 2026, creating a combined group with R$9.4 billion in revenue and roughly 5,900 annual medical-school seats, subject to antitrust review …
Peru’s Digemid has approved South Korean regenerative medicine company L&C Bio’s Re2O, an injectable based on human skin extracellular matrix, for commercialisation; the company plans to use Peru as a …
Mexican pharmaceutical manufacturer Sanfer has invested more than $40 million to expand pharmaceutical production capacity in Colombia, targeting export markets across Latin America and the Caribbean, according to a Sanfer-supported …
Chileans spend nearly US$100 million a year on weight-loss treatment, according to La Tercera, as seven generic semaglutide applications — including Laboratorio Chile’s Selfix — await regulatory review, putting Novo …
Bio-Techne shareholders have approved the $11.3 billion acquisition by Merck KGaA of Darmstadt, Germany, clearing a key procedural milestone as the deal moves toward a close expected by late 2026 …
Telix Pharmaceuticals agrees to acquire ITM Isotope Technologies Munich for up to $2.35 billion, securing isotope supply and adding ITM-11, a Phase 3 neuroendocrine tumour candidate that received an FDA …
Cristália’s Phase 1 safety trial of polilaminina for acute spinal cord trauma was scheduled to begin 24 September 2026 after authorisation from Brazil’s health regulator, Anvisa, in January — with …
The FDA approved belzutifan plus lenvatinib for adults with advanced clear cell renal cell carcinoma after prior immunotherapy, adding a second approved indication for belzutifan in 2026 and expanding Merck …
The FDA has approved insulin efsitora alfa-gobe (Onswik), Eli Lilly’s once-weekly basal insulin for adults with type 2 diabetes, making it the second such agent cleared in the US and …
The FDA has approved zilurgisertib (Atebrioz) for fibrodysplasia ossificans progressiva in patients aged 12 and older, making it the third approved FOP therapy and the second in five weeks.
You must be logged in to post a comment.